[New aspects of macrolides: contribution of roxithromycin]

Rev Med Interne. 1987 Nov-Dec;8(5):527-32. doi: 10.1016/s0248-8663(87)80206-0.
[Article in French]


Roxithromycin (RU 28965) is a new semi-synthetic derivative of erythromycin. Its antibacterial activity is of the same order as that of other macrolides, although its MIC's against Legionella pneumophila are lower. In double-blind comparative studies there was no significant difference in therapeutic effectiveness between roxithromycin and the reference antibiotics tested. However, this new macrolide exhibits exceptional pharmacological properties (prolonged half-life, excellent tissue penetration and intracellular activity), and it is very well tolerated both clinically and biochemically.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Bacterial Infections / drug therapy*
  • Chemical Phenomena
  • Chemistry
  • Humans
  • Leucomycins / pharmacokinetics
  • Leucomycins / pharmacology*
  • Leucomycins / therapeutic use*


  • Leucomycins